NCT03338998View on ClinicalTrials.gov

Efficacy, Safety and Tolerability of BAF312 Compared to Placebo in Patients With Intracerebral Hemorrhage (ICH).

PHASE2CompletedINTERVENTIONAL
Enrollment

32

Participants

Timeline

Start Date

December 24, 2017

Primary Completion Date

May 13, 2020

Study Completion Date

May 13, 2020

Conditions
Hemorrhagic StrokeIntracerebral Hemorrhage (ICH)
Interventions
DRUG

BAF312 solution

Solution for intravenous (IV) infusion - 4.5mg/4.5mL

DRUG

Matching Placebo for BAF312 solution

Solution for intravenous (IV) infusion - 0mg/4.5mL matching placebo

DRUG

BAF312 tablet

2 mg film-coated tablet

DRUG

Matching Placebo for BAF312 tablet

0 mg film-coated tablet matching placebo

Trial Locations (11)

21201

Novartis Investigative Site, Baltimore

22908

Novartis Investigative Site, Charlottesville

30303

Novartis Investigative Site, Atlanta

45219

Novartis Investigative Site, Cincinnati

48202

Novartis Investigative Site, Detroit

77024

Novartis Investigative Site, Houston

94304

Novartis Investigative Site, Palo Alto

97239

Novartis Investigative Site, Portland

06520

Novartis Investigative Site, New Haven

19104-4283

Novartis Investigative Site, Philadelphia

77030-3900

Novartis Investigative Site, Houston

Sponsors
All Listed Sponsors
lead

Novartis Pharmaceuticals

INDUSTRY